The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells: Role of Geranylgeranylation and Rho Proteins
Abstract
Abstract —3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (HRIs) have been recently shown to prevent atherosclerosis progression. Clinical benefit results from combined actions on various components of the atherosclerotic lesion. This study was designed to identify the effects of HRI on one of these components, the endothelial fibrinolytic system. Aortas isolated from rats treated for 2 days with lovastatin (4 mg/kg body wt per day) showed a 3-fold increase in tissue plasminogen activator (tPA) activity. In a rat aortic endothelial cell line (SVARECs) and in human nontransformed endothelial cells (HUVECs), HRI induced an increase in tPA activity and antigen in a time- and concentration-dependent manner. In SVARECs, the maximal response was observed when cells were incubated for 48 hours with 50 μmol/L HRI. An increase of tPA mRNA was also in evidence. In contrast, HRI inhibited plasminogen activator inhibitor-1 activity and mRNA. The effects of HRI were reversed by mevalonate and geranylgeranyl pyrophosphate, but not by LDL cholesterol and farnesyl pyrophosphate, and were not induced by α-hydroxyfarnesyl phosphonic acid, an inhibitor of protein farnesyl transferase. C3 exoenzyme, an inhibitor of the geranylgeranylated-activated Rho protein, reproduced the effect of lovastatin on tPA and plasminogen activator inhibitor-1 activity and blocked its reversal by geranylgeranyl pyrophosphate. The effect of HRI was associated with a disruption of cellular actin filaments without modification of microtubules. A disrupter of actin filaments, cytochalasin D, induced the same effect as lovastatin on tPA, whereas a disrupter of microtubules, nocodazole, did not. In conclusion, HRI can modify the fibrinolytic potential of endothelial cells, likely via inhibition of geranylgeranylated Rho protein and disruption of the actin filaments. The resulting increase of fibrinolytic activity of endothelial cells may contribute to the beneficial effects of HRI in the progression of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Jaffe, E. A., Nachman, R. L., Becker, C. G., & Minick, C. R. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107470 · Cited by 6,856
Ridley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260406 · Cited by 2,717
The pathogenesis of coronary artery disease and the acute coronary syndromes (First of two parts)
Fuster, V. (1992) · New England Journal of Medicine · Cited by 1,954
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Steinbrecher, U. P., Parthasarathy, S., Leake, D. S., Witztum, J. L., & Steinberg, D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.12.3883 · Cited by 1,626
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
The plasminogen activator/plasmin system.
Vassalli, J. D., Sappino, A. P., & Belin, D. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115405 · Cited by 1,164
(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
Regulation of differentiated properties and proliferation of arterial smooth muscle cells.
Thyberg, J., Hedin, U., Sjölund, M., Palmberg, L., & Bottger, B. A. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.6.966 · Cited by 553
Chardin, P., Boquet, P., Madaule, P., Popoff, M. R., Rubin, E. J., & Gill, D. M. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03477.x · Cited by 526
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
Kasiske, B. L., O'donnell, M. P., Cleary, M. P., & Keane, W. F. (1988) · Kidney International · doi:10.1038/ki.1988.51 · Cited by 409
Ny, T., Sawdey, M., Lawrence, D., Millan, J. L., & Loskutoff, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.6776 · Cited by 379
Post-translational modifications of p21rho proteins.
Adamson, P., Marshall, C. J., Hall, A., & Tilbrook, P. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)88661-1 · Cited by 335
Kita, T., Brown, M. S., & Goldstein, J. L. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109938 · Cited by 305
Kasiske, B. L., O'Donnell, M. P., Garvis, W. J., & Keane, W. F. (1988) · Circulation Research · doi:10.1161/01.res.62.2.367 · Cited by 291
Plasminogen Activator Expression in Human Atherosclerotic Lesions
Lupu, F., Heim, D. A., Bachmann, F., Hurni, M., Kakkar, V. V., & Kruithof, E. K. O. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.9.1444 · Cited by 188
Bacterial toxins that target Rho proteins.
Aktories, K. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119245 · Cited by 171
Lovastatin inhibits proliferation of rat mesangial cells.
O'Donnell, M. P., Kasiske, B. L., Kim, Y., Atluru, D., & Keane, W. F. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116204 · Cited by 168
Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors
Desager, J.-P., & Horsmans, Y. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631050-00003 · Cited by 167
Plasminogen activator in mouse and rat oocytes: Induction during meiotic maturation
Huarte, J., Belin, D., & Vassalli, J.-D. (1985) · Cell · doi:10.1016/0092-8674(85)90184-9 · Cited by 162
Regulation of intracellular actin polymerization by prenylated cellular proteins
Fenton, R. G., Kung, H., Longo, D., & Smith, M. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.117.2.347 · Cited by 116
Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator
Edelberg, J. M., Gonzalez–Gronow, M., & Pizzo, S. V. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90203-o · Cited by 111
Latron, Y., Chautan, M., Anfosso, F. J., Alessi, M., Nalbone, G., Lafont, H., & Juhan-Vague, I. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.6.1821 · Cited by 106
Hypofibrinolysis in patients with hypertension and elevated cholesterol
Jansson, J., Johansson, B. H., Boman, K., & Nilsson, T. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00352.x · Cited by 92
Munro, E., Patel, M., CHAN, P., Betteridge, L. J., Clunn, G. F., Gallagher, K. L., Hughes, A. D., Schächter, M., Wolfe, J. H. N., & Sever, P. S. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb01074.x · Cited by 87
Cellular receptors for the plasminogen activators
Bu, G., Warshawsky, I., & Schwartz, A. L. (1994) · Blood · doi:10.1182/blood.v83.12.3427.3427 · Cited by 82
Botteri, F. M., Ballmer‐Hofer, K., Rajput, B., & Nagamine, Y. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38302-4 · Cited by 75
Irigoyen, J. P., Besser, D., & Nagamine, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.3.1904 · Cited by 75
Lengyel, E. R., Stepp, E., Gum, R. J., & Boyd, D. D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.39.23007 · Cited by 73
Increased Plasma Fibrinogen and Platelet-Aggregates in Type II Hyperlipoproteinaemia
Lowe, G. D. O., Drummond, M. M., Third, J. L. H. C., Bremner, W. F., Forbes, C. D., Prentice, C. R. M., & Lawrie, T. D. V. (1979) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657051 · Cited by 72
Buchwald, H., Campos, C. T., Boen, J. R., Nguyen, P. A., & Williams, S. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)80006-3 · Cited by 69
Lee, J. S., von der Ahe, D., Kiefer, B., & Nagamine, Y. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.15.3365 · Cited by 55
Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease
Bevilacqua, M., Bettica, P. U., Milani, M., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00684-4 · Cited by 55
The coagulation and fibrinolysis systems and atherosclerosis.
Tanaka, K., & Sueishi, K. (1993) · PubMed · Cited by 46
HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture
Iimura, O., Vrtovsnik, F., Terzi, F., & Friedlander, G. (1997) · Kidney International · doi:10.1038/ki.1997.418 · Cited by 44
Self-citation[26] Plasminogen activators and their inhibitors
Loskutoff, D. J., & Schleef, R. R. (1988) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(88)63028-x · Cited by 34
Mongiardo, R., Finocchiaro, M. L., Beltrame, J. F., Pristipino, C., Lombardo, A., Cianflone, D., Mazzari, M. A., & Maseri, A. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00230-5 · Cited by 20
Cited by
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Takemoto, M., & Liao, J. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098486 · Cited by 1,272
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Metadata
- Authors
- Essig, M., Nguyen, G., Prié, D., Escoubet, B., Sraer, J.-D., & Friedlander, G.
- Venue
- Circulation Research
- Published
- 1998-10-05
- Volume
- 83
- Issue
- 7
- Pages
- 683-690
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2145448066
- Cited by
- 316
- References
- 45
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.